Latest Breaking News On - Hironoshin nomura - Page 12 : comparemela.com
Sosei Heptares and InveniAI Enter a Multi-target AI-powered and GPCR-focused Drug Discovery Collaboration
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Sosei Heptares Initiates Phase 1 Trial With Novel Small-Molecule CGRP Antagonist Under Collaboration With Biohaven
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
TOKYO and CAMBRIDGE, England, May 19, 2021 /PRNewswire/ Sosei Group Corporation ( the Company ) (TSE: 4565) has been notified by Pfizer that the first subject in a clinical trial has been dosed with a new drug candidate nominated from the multi-target drug discovery collaboration between the two companies. Achievement of this milestone triggers a payment of US$5 million to Sosei Heptares. This candidate was nominated for advancement by Pfizer in December 2019 generating a US$3 million milestone payment at that time.
Pfizer nominated three distinct clinical candidates from the collaboration with Sosei Heptares during 2019, all of which are now progressing in Phase I clinical trials. These candidates have also now been disclosed by Pfizer as:
Sosei Heptares announces that the third novel drug candidate from its multi-target drug discovery collaboration with Pfizer has started clinical trials
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Sosei Heptares Operational Highlights and Consolidated Results for the First Quarter 2021
News provided by
Share this article
Share this article
TOKYO and CAMBRIDGE, England, May 12, 2021 /PRNewswire/ Sosei Group Corporation ( the Company ) (TSE: 4565) provides an update on operational activities and reports its consolidated results for the first quarter ended 31 March 2021. The full report can be accessed by clicking here.
Shinichi Tamura, Chairman, President and CEO of Sosei Heptares, commented: We continue to make good progress expanding our drug discovery business and remain well positioned to capitalize on a range of growth opportunities. We have initiated several exciting new technology collaborations designed to enhance our world-leading discovery platform and extend the reach of its application, including beyond GPCRs for the first time. We have made good progress with our partnered programs, which have delivered multiple milestones and generated important revenue